CA
MRNA icon

CoreCap Advisors’s Moderna MRNA Stock Holding History

CoreCap Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$322K Buy
4,595
+3,931
+592% +$203K 0.01% 691
2026
Q1 		$33.7K Buy
664
+139
+26% +$6.49K ﹤0.01% 1475
2025
Q4 		$15.5K Sell
525
-700
-57% -$19K ﹤0.01% 1788
2025
Q3 		$31.6K Sell
1,225
-10
-0.8% -$279 ﹤0.01% 1496
2025
Q2 		$34.1K Buy
1,235
+121
+11% +$3.19K ﹤0.01% 1405
2025
Q1 		$31.6K Sell
1,114
-4
-0.4% -$142 ﹤0.01% 1362
2024
Q4 		$46.5K Sell
1,118
-98
-8% -$4.68K ﹤0.01% 1210
2024
Q3 		$81.3K Buy
1,216
+28
+2% +$2.57K ﹤0.01% 1003
2024
Q2 		$141K Buy
1,188
+16
+1% +$2.02K 0.01% 429
2024
Q1 		$125K Buy
+1,172
New +$118K 0.01% 769
2022
Q4 		$387K Buy
+2,155
New +$352K 0.03% 399
2022
Q3 		– Sell
-1,797
Closed -$257K – 1482
2022
Q2 		$257K Buy
+1,797
New +$257K 0.02% 453
2022
Q1 		– Sell
-859
Closed -$218K – 1475
2021
Q4 		$218K Buy
+859
New +$251K 0.01% 516

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

CoreCap Advisors's MRNA Position: Q2 2026 in Review

CoreCap Advisors increased its Moderna (MRNA) stake by 592% in Q2 2026, buying an estimated $203K and bringing the position to 4,595 shares worth $322K. The position accounts for 0.01% of the portfolio, ranked #691.

CoreCap Advisors first reported a position in MRNA in Q4 2021 and has held it in 13 quarters since. The position peaked at $387K in Q4 2022. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • CoreCap Advisors held 4,595 shares of Moderna worth $322K as of Q2 2026.
  • CoreCap Advisors bought 3,931 Moderna shares in Q2 2026, an estimated $203K.
  • Moderna made up 0.01% of CoreCap Advisors's portfolio in Q2 2026, its #691 holding.
  • CoreCap Advisors first reported a position in Moderna in Q4 2021 and has held it in 13 quarters since.
  • CoreCap Advisors's Moderna position peaked at $387K in Q4 2022.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.